Effects of an extended version of the Lee Silverman Voice Treatment on voice and speech in Parkinson's disease.

PURPOSE: The present study examined vocal SPL, voice handicap, and speech characteristics in Parkinson's disease (PD) following an extended version of the Lee Silverman Voice Treatment (LSVT), to help determine whether current treatment dosages can be altered without compromising clinical outcomes....

Descripción completa

Detalles Bibliográficos
Publicado en:American Journal of Speech-Language Pathology Vol. 16; no. 2; pp. 95 - 108
Autores principales: Spielman J, Ramig LO, Mahler L, Halpern A, Gavin WJ
Formato: research tables/charts Journal Article
Publicado: American Speech-Language-Hearing Association May2007
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106147078&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 106147078
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        10580360
        5E7
      jtl: American Journal of Speech-Language Pathology
      issn: 10580360
      maglogo: N
    pubinfo:
      dt: May2007
      vid: 16
      iid: 2
      pid: 42
      pub: American Speech-Language-Hearing Association
      place: Rockville, Maryland
    artinfo:
      ui:
        106147078
        2009578812
        10.1044/1058-0360(2007/014)
        NLM17456888
        106147078
      ppf: 95
      ppct: 13
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Effects of an extended version of the Lee Silverman Voice Treatment on voice and speech in Parkinson's disease.
      aug:
        au:
          Spielman J
          Ramig LO
          Mahler L
          Halpern A
          Gavin WJ
        affil: National Center for Voice and Speech, 1101 13th Street, Denver, CO 80204, USA. jspielman@dcpa.org
      sug:
        subj:
          Dysarthria Therapy
          Parkinson Disease Therapy
          Rehabilitation, Speech and Language
          Speech Therapy Methods
          Voice Disorders Therapy
          Aged
          Aged, 80 and Over
          Audiorecording
          Colorado
          Descriptive Statistics
          Experimental Studies
          Female
          Funding Source
          Learning
          Male
          Middle Age
          Post Hoc Analysis
          Pretest-Posttest Design
          Prospective Studies
          Self Care
          Sound Spectrography
          Speech Acoustics
          Speech Production Measurement
          T-Tests
          Treatment Outcomes
          Two-Way Analysis of Variance
          Voice Quality
          Human
          Aged: 65+ years
          Aged, 80 & over
          Middle Aged: 45-64 years
          Female
          Male
      ab: PURPOSE: The present study examined vocal SPL, voice handicap, and speech characteristics in Parkinson's disease (PD) following an extended version of the Lee Silverman Voice Treatment (LSVT), to help determine whether current treatment dosages can be altered without compromising clinical outcomes. METHOD: Twelve participants with idiopathic PD received the extended treatment version (LSVT-X), similar to LSVT except that it was administered twice a week in 1-hr sessions over 8 weeks and required substantially more home practice. Recordings were made in a sound-treated booth immediately before and after treatment, and again 6 months later. Vocal SPL was measured for 4 different tasks and compared with data from a previous study, in which participants with PD received traditional LSVT 4 times a week for 4 weeks. Listener ratings were conducted with audio samples from both studies, using sentence pairs from a standard passage. LSVT-X participants completed the Voice Handicap Index (VHI) before each set of recordings. RESULTS: Participants receiving LSVT-X significantly increased vocal SPL by 8 dB after treatment and maintained increased vocal SPL by 7.2 dB at 6 months. VHI scores improved for 25% of the LSVT-X participants following treatment, and listener ratings indicated audible improvement in speech. CONCLUSIONS: LSVT-X successfully increased vocal SPL (which was consistent with improvements following traditional LSVT), decreased perceived voice handicap, and improved functional speech in individuals with PD. Further large-scale research is required to truly establish LSVT-X efficacy.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N